Leo Pharma’s Spanish unit earned €97M in 2024, up 4% from 2023, led by dermatology (€61.2M, 67% of revenue). Biodermatology grew over 20%, driven by Adtralza....
Ysios Capital joined Adcendo's $135M Series B round, the EU's largest in biotech this year, enabling Adcendo to advance its cancer-targeting ADC pipeline. Based in Spain,...